Rocket Pharma Reaps $180M From Sale of FDA Drug Review Fast Pass
Rocket Pharmaceuticals received the rare pediatric disease priority review voucher with the accelerated FDA approval…
Rocket Pharmaceuticals received the rare pediatric disease priority review voucher with the accelerated FDA approval for Kresladi in March. The non-dilutive capital from the voucher’s sale will support a pipeline that includes a gene therapy in pivotal clinical testing for the rare genetic disorder Danon disease. The post Rocket Pharma Reaps $180M From Sale of…
The industry needs a framework that can translate clinical nuance into a consistent, trusted representation across systems and use cases. The post In the Age of AI, Interoperability Isn’t Enough: Why Healthcare Needs Shared Understanding, Not Just Shared Data appeared first on MedCity News.
How America’s outdated insurance model is failing at its most important job The post The Myth of Insurance Networks appeared first on MedCity News.
The gap between how nicotine use has evolved and how cessation treatment has evolved is a meaningful part of why quit rates have plateaued. The post Smoking Cessation’s Quiet Design Failure appeared first on MedCity News.
KFF Health News chief Washington correspondent Julie Rovner discussed Health and Human Services Secretary Robert F. Kennedy Jr.’s position on antidepressants on WAMU’s 1A on June 10. Click here to hear Rovner on 1A. KFF Health News journalist Rae Ellen Bichell discussed, on WBUR’s Here & Now on June 10, a recent investigation that found…
GLP-1 and cancer.Healthcare mortgages for gene therapies.Argentia vs. Chile: battle of the economies.Medicaid work rules explained.Watch the World Cup in English or en Español?
An OIG report found that the three largest Medicare Advantage insurers denied prior authorization requests for long-term acute care and inpatient rehabilitation at higher rates than other MA plans in 2024. The post OIG: 3 Largest MA Insurers Deny Prior Auth Requests at High Rates for Long-Term Acute Care, Inpatient Rehab appeared first on MedCity…
FDA concerns about Amgen’s Tavneos were sparked by securities fraud litigation against ChemoCentryx, the company that originally developed the rare disease drug. The FDA wants to withdraw Tavneos’s approval, citing safety risks and alleged manipulation of the drug’s clinical trial data. The post Amgen Turns to an Independent Review to Defend Rare Disease Drug in…
The healthcare industry is spending more than ever on AI — but according to executives from Oracle Health, HCA Healthcare and BJC Health, much of that investment could be wasted. During a panel this week at HFMA’s annual conference, they argued that no amount of sophisticated tech can overcome a broken, antiquated data foundation. The…
The issue of affordability has reignited a long-simmering battle between California’s medical industry and one of its largest health worker unions. SEIU-United Healthcare Workers West, with approximately 120,000 members, has put forward two ballot initiatives to cap the pay of medical executives and require community clinics to spend the vast bulk of their revenues on…